Endomyocardial Biopsy Market To Reach $543.00 Million By 2030

Endomyocardial Biopsy Market Growth & Trends

The global endomyocardial biopsy market size is expected to reach USD 543.00 million by 2022, registering a CAGR of 6.8% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to factors such as increasing prevalence of Cardiovascular Disorders (CVDs), rising demand for minimally invasive surgical procedures, and favorable reimbursement policies for coronary intervention procedures.

Increase in technological advancements and investment of multinational companies in the emerging economies serve as ideal opportunities for the growth and expansion of a market. There is a trend of healthcare reforms and advancements in technology for medical products and devices in the emerging economies. This creates an opportunity for manufacturers to introduce their products and capture a significant portion of the market. Countries like India, China and others are developing and are bringing about incremental changes to their healthcare systems providing enhanced treatment options to patients.

Furthermore, the availability of well-established healthcare infrastructure in developed countries enables easy accessibility to advanced diagnostic and treatment options. According to data published by the United Network for Organ Sharing, in 2022, over 4,111 heart transplants were performed in the U.S. As the number of heart transplants increases, the need for regular monitoring and early detection of rejection would also increase. This would further boost the demand for endomyocardial biopsy procedures.

The pandemic has highlighted the importance of regular monitoring and early detection of heart conditions among people which would further drive demand for the endomyocardial biopsy procedure in the coming years. Additionally, the adoption of remote monitoring technologies is expected to make endomyocardial biopsy procedures more accessible to patients, further supporting the growth of the market.

 Request a free sample copy or view report summary: Endomyocardial Biopsy Market Report

Endomyocardial Biopsy Market Report Highlights

• Based on product, the forceps segment captured the highest market share in 2022 owing to the development of new and improved forceps with better grip and precision

• Based on tip, the straight tip segment dominated the market in 2022, as the usage of straight tip minimizes the risk of tissue damage during the biopsy, ensuring that the collected tissue is suitable for accurate diagnosis

• Based on end-use, the hospitals segment is expected to dominate the market in 2022. Owing to factors such as increasing number hospitals globally coupled with increasing volume of biopsy procedures

• North America dominated the endomyocardial biopsy market and accounted for the largest revenue share of 44.5% in 2022 owing to the increasing number of geriatric population and well-developed healthcare infrastructure

Endomyocardial Biopsy Market Segmentation

Grand View Research has segmented the global endomyocardial biopsy market on the basis of product, tip, end-use, and region:

Endomyocardial Biopsy Product Outlook (Revenue, USD Million, 2018 - 2030)

• Forceps

• Accessories

Endomyocardial Biopsy Tip Outlook (Revenue, USD Million, 2018 - 2030)

• Maxi-curved

• Straight

• Pre-curved

• Others

Endomyocardial Biopsy End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Ambulatory Surgical Centers

• Others

Endomyocardial Biopsy Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

• U.S.

• Canada

• Europe

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

• Asia Pacific

• Japan

• China

• India

• Australia

• South Korea

• Thailand

• Latin America

• Brazil

• Mexico

• Argentina

• Middle East & Africa

• South Africa

• Saudi Arabia

• UAE

• Kuwait

List of Key Players of Endomyocardial Biopsy Market

• Argon Medica Devices, Inc.

• Cordis

• Mermaid Medical

• Terum Corporation

• Scholten Surgical Instruments, Inc.

• Changzhou Lookmed Medical Instrument Co., Ltd.

• Fehling Instruments